sec filing
QT
NASDAQ · QTTB
Q32 Bio Inc.
Healthcare · Biotechnology
$11.17
Up+$0.26 (+2.38%)
Updated Sep 16, 2026, 10:16 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 39.25M
- P/E ratio
- -0.93
- Dividend yield
- 0.00%
- 52-week range
- $4.40 – $23.57
- Volume
- 602.6K
- Avg. volume
- 3.07M
Price performance
QTTB price history
1M range · 20 trading sessions · Daily adjusted prices
QTTB closed at $11.17 after 20 trading sessions, down 26.95% for the selected period.
- Last close
- $11.17
- Period change
- -26.95%
- Period low
- $10.72
- Period high
- $16.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $10.77 | $11.29 | $10.51 | $11.17 | 602.6K |
| Sep 14, 2026 | $10.96 | $11.28 | $10.63 | $10.91 | 870.61K |
| Sep 11, 2026 | $10.82 | $11.27 | $10.45 | $11.10 | 1.82M |
| Sep 10, 2026 | $11.00 | $11.08 | $10.54 | $10.72 | 937.78K |
| Sep 9, 2026 | $11.61 | $11.95 | $11.065 | $11.14 | 488.86K |
| Sep 8, 2026 | $12.00 | $12.00 | $11.5659 | $11.69 | 592.92K |
| Sep 4, 2026 | $12.60 | $12.70 | $11.50 | $11.99 | 853.81K |
| Sep 3, 2026 | $13.52 | $13.59 | $12.74 | $12.80 | 491.58K |
| Sep 2, 2026 | $14.42 | $14.55 | $13.35 | $13.59 | 434.82K |
| Sep 1, 2026 | $14.77 | $14.77 | $14.18 | $14.36 | 331.61K |
| Aug 31, 2026 | $14.85 | $15.32 | $14.75 | $14.87 | 349.85K |
| Aug 28, 2026 | $15.91 | $16.25 | $14.92 | $15.03 | 353.91K |
| Aug 27, 2026 | $16.08 | $16.30 | $15.93 | $16.15 | 203.36K |
| Aug 26, 2026 | $16.13 | $16.52 | $15.8001 | $16.18 | 327.15K |
| Aug 25, 2026 | $16.36 | $16.98 | $16.06 | $16.32 | 599.09K |
| Aug 24, 2026 | $16.50 | $16.66 | $15.50 | $16.36 | 691.06K |
| Aug 21, 2026 | $15.89 | $16.29 | $15.72 | $15.97 | 341.53K |
| Aug 20, 2026 | $15.80 | $16.15 | $15.51 | $15.86 | 389.51K |
| Aug 19, 2026 | $15.56 | $15.93 | $15.25 | $15.84 | 267.01K |
| Aug 18, 2026 | $15.65 | $16.04 | $15.04 | $15.29 | 319.36K |
Latest QTTB news
The latest Smart Investors Daily articles mentioning QTTB.
Stock researchCompany · Overview
QTTB research
Overview
Company profile and research snapshot.
Company profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $63.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Morgan Stanley | Overweight | — |
| Jul 28, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 13, 2026 | Oppenheimer | Outperform | — |
| Jul 13, 2026 | Wells Fargo | Overweight | — |
| May 22, 2026 | Mizuho | Outperform | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.